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I n t r o d u c t i o n. Hodgkin’s disease is usually characterised by favourable prognosis, even in its advanced form. Primary re-
sistance and relapse, in particular in the period prior to a year from achieving remission, is most negatively affected progno-
stically. Standard treatment leads to secondary remission only in 29% of patients undergoing treatment. Recently, the treatment
of resistant and recurrent Hodgkin’s disease employs high dose chemotherapy combined with autologous haematopoietic cell
transplantation
M a t e r i a l  a n d  m e t h o d s. The effect of such treatment in 40 patients is presented. The therapeutic indications for trans-
plantation were: primary resistance in 15 cases; partial remission in two; early relapse in five; late relapse in two; second and
further relapses in the remaining 16 cases. The haematopoietic cells originated exclusively from peripheral blood. The trans-
plantation was preceded by cytoreductive chemotherapy according to the DexaBEAM scheme, in standard doses. At the time
of transplantation complete remission was observed in 15 patients, partial remission in 17, and in eight cases the disease pro-
gressed. CBV was utilised for conditioning, and replaced later by BEAM.
Re s u l t s.  Remission was achieved in 32 out of 40 cases, partial remission was noted in five cases and progression of the dise-
ase in on. Haematological recovery was reasonably quick in a majority of patients, and no cases of lack of or incomplete engra-
ftment of bone marrow were observed. After 100 days after transplantation, the progression of the disease was  the major death
cause. Only one patient died due to haematological complications not associated with Hodgkin’s disease, i.e. acute myelobla-
stic leukaemia. Three year overall survival was assessed at 56%, and disease free survival – at 42%. The factors negatively af-
fecting prognosis were: primary and secondary resistance to chemotherapy, and LD histopathological type. Relapse of Hodg-
kin’s disease was the most common reason for ineffective treatment. 
C o n c l u s i o n s. High dose chemotherapy proved to be a very effective method in the treatment of Hodgkin’s disease,
considering the fact that it was impossible to achieve remission only  in six cases. The high percentage of relapses observed, ho-
wever, remains a challenge. Relapses of Hodgkin’s disease occurred, in particular, in patients who were resistant to previous
chemotherapy and in those resistant to intensified treatment preceding transplantation. The results in the first group were unfa-
vourable to the extent that therapeutic indications for high dose chemotherapy were considered questionable.
Wysoko dawkowana chemioterapia
w po∏àczeniu z przeszczepianiem autologicznych komórek krwiotwórczych
w leczeniu opornych i nawrotowych postaci ziarnicy z∏oÊliwej
W s t ´ p. Ziarnica z∏oÊliwa jest zazwyczaj chorobà o dobrym rokowaniu, nawet przy rozpoznaniu w okresie znacznego jej za-
awansowania. Pierwotna opornoÊç na chemioterapi´ oraz nawrót, szczególnie przed up∏ywem roku od zakoƒczenia leczenia,
bardzo niekorzystnie wp∏ywajà na prognozowanie. Klasyczne leczenie jest w stanie doprowadziç do kolejnej remisji zaledwie
oko∏o 29% pacjentów. W leczeniu pierwotnie opornej oraz nawrotowej ziarnicy z∏oÊliwej stosuje si´ w ostatnich latach wyso-
ko dawkowanà chemioterapi´, po∏àczonà z przeszczepianiem autologicznych komórek krwiotwórczych.
M a t e r i a ∏ y  i m e t o d y. Zaprezentowano efekty powy˝szego leczenia, przeprowadzonego u 40 chorych. Wskazaniami by∏y:
pierwotna opornoÊç u 15, cz´Êciowa remisja u 2, wczesny, pierwszy nawrót u 5, póêny nawrót u 2, drugi i nast´pne nawroty
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Introduction
Hodgkin’s disease is usually often characterised by favo-
urable prognosis, and even in its advanced form, com-
plete remission after chemotherapy was observed in 64-
-84% of the cases [1]. In a majority of cases remission
leads to recovery. Relapse, in particular in the period
prior to a year from achieving remission is, in turn, most
negatively affected prognostically. Standard treatment
led to secondary remission merely in 29% of the patients
undergoing treatment [2]. The prognosis is yet more unfa-
vourable in patients, who did not respond to chemothera-
py. Long-term remission was observed in only 0-20% of
the patients [3].
In the last decade, high dose chemotherapy combined
with transplantation of haematopoietic cells has been em-
ployed in patients with unfavourable prognoses [4, 5]. Re-
gardless of the high number of reports concerning the ef-
fectiveness of the procedures mentioned above, randomi-
sed studies, that would explicitly confirm their advantage
over classical chemotherapy, were not conducted. Besi-
des, it was not established which patients may take the
most advantage of high dose chemotherapy. Hence the
importance of retrospective analysis. In our work we have
decided to present our own experience in the employ-
ment of high dose chemotherapy combined with trans-
plantation of haematopoietic progenitor cells in patients
suffering from resistant and recurrent Hodgkin’s disease.
Materials and methods
40 patients with Hodgkin’s disease underwent treatment em-
ploying autologous transplantation of progenitor cells between
1995-1999. The group consisted of 19 women and 21 men aged
between 17 and 50 years (median 29). Among those qualified for
treatment were 25 patients with a histopathologically diagno-
sed NS type, 11 with an MC type and four with an LD type.
The therapeutic indications for transplantation were as follows:
primary resistance in 15 patients; partial remission in two; early,
primary relapse in five; late relapse in two; second and further
relapses in the remaining 16 patients. Primary resistance was
recognised as lack of complete remission after a minimum of two
cycles of standard treatment. Early relapse was defined as such
that occurred prior to one year from achieving remission. The
first transplanted patient underwent conditioning immediately
after completing second line treatment, the symptoms of active
disease being evident. In the remaining patients, the autologous
transplantation was preceded by cytoreductive chemotherapy
according to the Dexa BEAM scheme in standard doses [6].
Generally two cycles of treatment were employed. If earlier re-
mission was observed only one cycle was administered. In one
case, due to the progression of the disease after Dexa BEAM
treatment, DHAP was administered, but to no avail. At the time
of transplantation complete remission was observed in 15 pa-
tients, partial remission in 17, and in eight cases the disease
progressed. To verify remission computer tomography and other
image examinations were used. In cases of controversial lesions
in the mediastinum diagnosis included gallium scan.
Progenitor cells utilised in transplantation originated exc-
lusively from peripheral blood. The mobilisation consisted of
Dexa BEAM chemotherapy, followed by daily subcutaneous
administration of rhG-CSF (Neupogen, Roche). G-CSF was ad-
ministered in doses of 300 µg in patients, weighing under 60 kg
and 480 µg in the remaining patients. Cells were collected after
nadir on growth of leucocytosis to a level of above 6.0 G/l (from
November 1998 – 10.0 G/l). Cytapheresis was conducted by the
cell separator Fenwall CS3000 Plus. The products of cytaphere-
sis were assessed basing on the number of mononuclear cells,
CD34 positive cells and CFU-GM (granulocyte-monocyte colo-
ny forming units) cells in relation to patients weight. Cell collec-
tions were terminated on receipt of a number of CD34+ cells
above 2.0x106/kg of the patients’ b. w. In the conditioning regi-
men CBV was initially utilised (Cyclophosphamide 7200 mg/m2,
BCNU 450 mg/m2, Etoposide 1600 mg/m2). In patients, who
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u pozosta∏ych 16 chorych. Komórki krwiotwórcze wykorzystywane do przeszczepu pochodzi∏y wy∏àcznie z krwi obwodowej. Prze-
szczep poprzedza∏o zazwyczaj leczenie cytoredukcyjne, wed∏ug schematu DexaBEAM. W chwili przeszczepu 15 chorych by∏o
w ca∏kowitej remisji, 17 w cz´Êciowej, a u 8 mia∏a miejsce progresja choroby. W kondycjonowaniu stosowano poczàtkowo CBV,
potem BEAM.
W y n i k i.  SpoÊród 40 chorych poddanych powy˝szemu leczeniu, u 32 dosz∏o do remisji, 5 znalaz∏o si´ w cz´Êciowej remisji,
a w jednym przypadku dosz∏o do progresji choroby. W wi´kszoÊci wypadków regeneracja hematologiczna by∏a stosunkowo szyb-
ka, nie obserwowano przypadków braku lub niepe∏nego wszczepienia si´ szpiku. ÂmiertelnoÊç oko∏oprzeszczepowa wynios∏a
5%. W okresie póêniejszym ni˝ w 100 dniu po przeszczepie w zdecydowanej wi´kszoÊci przypadków przyczynà zgonu by∏a pro-
gresja choroby. Z powodu powik∏aƒ hematologicznych, niezale˝nych od ziarnicy, zmar∏a tylko jedna osoba; dosz∏o u niej do
rozwini´cia si´ objawów ostrej bia∏aczki szpikowej. Szacowane 3-letnie ca∏kowite prze˝ycie wynosi 56%, bez objawów progre-
sji choroby 42%. Czynnikami obcià˝ajàcymi rokowanie okaza∏y si´: pierwotna oraz wtórna opornoÊç na chemioterapi´
oraz typ histopatologiczny LD. Przyczynà niepowodzenia leczenia by∏ zazwyczaj nawrót ziarnicy.
W n i o s k i.  Wysoko dawkowana chemioterapia okaza∏a si´ bardzo skutecznà metodà eliminacji nowotworu, tylko u 6 cho-
rych nie uzyskano ca∏kowitej remisji. Istotnym problemem pozostaje wysoki odsetek obserwowanych nawrotów. Mia∏y one miej-
sce zazwyczaj u chorych, od samego poczàtku wykazujàcych opornoÊç, a tak˝e u niewra˝liwych na intensyfikowanà chemio-
terapi´, poprzedzajàcà przeszczep. Z∏e rezultaty uzyskane w pierwszej z wymienionych grup ka˝à zastanowiç si´ nad zasadno-
Êcià stosowania tej metody leczenia.
Key words: resistant and recurrent Hodgkin’s disease, high dose chemotherapy, autologous haematopoietic cell trans-
plantation, CBV, BEAM
S∏owa kluczowe: Pierwotnie oporna oraz nawrotowa ziarnica z∏oÊliwa, wysoko dawkowana chemioterapia, przeszczepia-
nie autologicznych komórek krwiotwórczych, CBV, BEAM
did not achieve remission during previous treatment Cisplatin
(150 mg/m2) was additionally introduced. From May 1997 the
standard procedure for all patients was conditioning regimen
according to the BEAM scheme (BCNU 300 mg/m2, Etoposide
1200 mg/m2, ARA-C 1600 mg/m2, Melphalan 140 mg/m2).
In the period following transplantation antibacterial (qu-
inolone group), anti fungal (Fluconazole) and antiviral (Aciclo-
vir up to day +30) prophylaxis was introduced. At a later time
antibacterial prophylaxis was discontinued and Acyclovir admi-
nistration was extended to day +100. Confronted with a high risk
of hepatitis B infection, in spite of preventive vaccinations (60%
transplanted patients were infected between 1995-1996), com-
mencing from 1997 routine administration of anti-HBs serum
(Hepatect) was introduced. Since then no new infection was
noted. Haematopoietic growth factors were not routinely used.
Seven patients who were in complete remission at the time of
transplantation had Proleukin and Roferon administered im-
mediately after achieving haematological recovery, in order to
decrease the risk of relapse [7]. Due to the small size of this
group and short observation time independent analysis of the
group is not possible.
Statistical analysis concerned the following parameters:
histopathological type, sex, presence of clinical symptoms, clini-
cal progression of the disease at the time of transplantation, re-
sponse to prior treatment, therapeutic indications to transplan-
tation (resistance, early or late relapse) and the type of conditio-
ning regimen (BEAM, CBV). Statistical analysis was conducted
based on the Kaplan-Meier method, utilising the log-rank test.
The STATISTICA 5.0 (StatSoft Inc.) programme was used.
Results
From among 40 patients who underwent autologous pro-
genitor cell transplantation in 38 cases complete haema-
tological recovery was achieved. Two patients died due
to the toxicity of the procedure employed, namely, due to
pneumonia and septic shock at the time of bone marrow
aplasia. In the early post transplant period another death
occurred due to rapid progression of the disease accom-
panied by prompt haematological recovery. In a great
majority of patients reconstitution of haematopoiesis was
quick and complete: leucocytosis of above 1.0 G/l was
achieved on day +13 (range 7-26), neutrophils achieved
a number of 0.5 G/l on day +14 (range 10-24), platelets
reached a number of 50 G/l on day 16 (range 10-90) after
progenitor cell infusion.
After transplantation no symptoms of active disease
were observed in 32 patients, partial remission was noted
in five cases and in one case progression of the disease
was noticed. Regression of symptoms of the disease was
achieved in 18 cases, the remaining 14 patients being in re-
mission at the time of initiating preparative chemotherapy,
the conducted transplantation constituting consolidation
therapy. At a period later than 100 days after transplanta-
tion the progression of the disease was the cause of death
in a majority of cases. Only one patient died due to ha-
ematological complications independent of Hodgkin’s di-
sease. This patient developed acute myelogenous leuka-
emia. Cytogenetic examination (7q-) showed that leuka-
emia could have been induced by earlier chemo- or
radiotherapy. At the time of death the patient was in com-
plete remission of Hodgkin’s disease.
At present 28 of the 40 patients who underwent au-
tologous progenitor cell transplantation are alive. At an
average time of observation of 507+ days (range 14-1520)
assessed three year survival in the examined group is
56% and three year disease free survival is 42%. The ave-
rage time of relapse was 527 days, the latest one observed
being on day 1097. In two patients relapse occurred later
than two years after transplantation.
The most important factor for successful treatment
was sensitivity to chemotherapy preceding transplanta-
tion. Patients in complete remission at the time of trans-
plantation showed statistically significant favourable pro-
gnosis concerning overall survival (p=0.006) in compari-
son to those in whom progression of the disease was
observed following preceding therapy. Similarly, favoura-
ble prognosis concerning disease free survival, was evident
in patients with partial remission (p=0.020). No statisti-
cally significant prognostic factors were revealed between
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Tab. 1. Patients characteristics
Total number of patients 40
Age, years 29
Range 17- 50
Sex
Female 19
Male 21
Histopatology
NS 25
MC 11
LD 4
Indications for the transplant
Primary resistance 15
Partial remission 2
Early relapse 5
Late relapse 2
Secon and further 16
Status at transplant
Complete remission 15
Partial remission 17
Progressive disease 8
Fig. 1. Actuarial overall survival in 40 patients transplanted for Hodg-
kin’s disease
patients in complete or partial remission at the time of
transplantation.
As was already mentioned the therapeutic indica-
tions for high dose chemotherapy and progenitor cell
transplantation were as follows: primary resistance to
standard doses of chemotherapy, early relapse after stan-
dard therapy and further relapses of the disease. The gro-
up with the least favourable prognosis consisted of pa-
tients with primary resistance to chemotherapy. The risk
of disease progression was significantly higher in that gro-
up than for those who underwent transplantation due to
relapse (p=0.016). Assessed three – year survival was
39% and the longest survival with no progression of the
disease was 536 days. The results of the therapy in pa-
tients treated for relapse were entirely different: three
year overall survival was assessed at 71%, disease free su-
rvival being 64%. As indicated above histopathological
diagnosis was also prognostically significant. Although
only four patients with LD type were transplanted, their
prognosis concerning survival was significantly worse than
in the case of NS type (p=0.041). It  was not confirmed
that the employed conditioning regimen had any influ-
ence on the achieved results for the reason that late effects
of the utilisation of the CBV scheme with or without Ci-
splatin did not differ significantly from those achieved by
means of the BEAM scheme. No advantages resulting
from increasing the dose of Etoposide were observed.
From among five patients treated in this manner two died
in the early post-transplant period and two others suffered
from early relapse. The small size of the group does not
however allow us to reach univocal conclusions.
Discussion
Chemotherapy combined with autologous progenitor cell
transplantation has become a standard procedure in the
treatment of resistant and recurrent Hodgkin’s disease. In
1998 the European Group for Blood and Marrow Trans-
plantation registered 1087 such procedures [8]. Trans-
plantations from peripheral blood are preferred for the
reason that a shorter time of haematological recovery is
involved, entailing lower costs [9]. Moreover the risks as-
sociated with employing this procedure are lower than
in the case of utilising progenitor cells from bone marrow
[10]. Those are the reasons for introducing peripheral
progenitor cell transplantations in our department. Only
two treatment-related deaths have been registered, from
among 40 patients who underwent transplantation. This
result does not differ from those reported by other au-
thors [11, 12]. In the majority of patients haematological
recovery was reasonably quick and no cases of either lack
of nor incomplete engraftment of bone marrow were ob-
served.
High dose chemotherapy has proved to be a very ef-
fective method of eliminating tumours. Only one patient
was completely and five partially resistant to this treat-
ment. Unfortunately, the high percentage of relapses ob-
served remains a major problem. The type of conditioning
regimen is not a decisive risk factor for relapses. Attempts
to increase the dose of Etoposide from 1200 to 1600
mg/kg of b.w. caused merely a noticeable increase of the
toxicity of treatment. Relapses of Hodgkin’s disease oc-
curred particularly in patients who were resistant to che-
motherapy and in those resistant to intensified treatment
preceding transplantation. The results in the first of the
mentioned groups were unfavourable to the extent that
therapeutic indications for high dose chemotherapy were
considered questionable. Reports from other works sug-
gest that bone marrow transplantation should be utilised
even though its advantage over standard chemotherapy is
not great. The results of retrospective studies comparing
survival of patients, registered in the data base of the
French Society of Bone Marrow Transplantation (Society
Franchise de Gruff de Moelle), who did not achieve re-
mission, and treated by means of intensified or standard
chemotherapy, revealed a tendency for increased survival
among patients who underwent transplantation (the diffe-
rence in six year survival at a level of significance α=0.58)
[13]. Earlier, similar reports originating from Stanford
indicated advantages only in relation to disease free survi-
val [14]. The procedure presently adopted in order to im-
prove the prognosis of this group of patients is to admini-
ster a maximally large dose of standard chemotherapy at
the initial stage of treatment, to prevent the development
of resistance. The presented results show the advantage of
this procedure over standard chemotherapy [15].
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Fig. 2. Disease free survival of 40 transplanted patients (median 528
days)
Fig. 3. Comparison of overall survival according to status at transplan-
tation (complete remission versus progressive disease)
Sensitivity to chemotherapy remains an impor-
tant prognostic factor also in the case of recurrent di-
sease [16]. Unfavourable prognosis is associated with re-
lapse occurring earlier than one year after terminating
standard treatment and also in the case of successive re-
lapses [17]. Those are simultaneously the basic thera-
peutic indications for autologous progenitor cell trans-
plantation. The results of treatment of late relapse (over
12 months after achieving remission) are favourable.
Utilising high dose chemotherapy in such instances is
questionable [18].
On deciding to utilise high dose chemotherapy one
must remember about potential complications related to
the transplantation. According to the French Society of
Bone Marrow Transplantation, quoted above, the risk of
death in the case of toxicity of the transplantation is 8%,
and the possibility of the occurrence of secondary neopla-
sia in the period of five years after transplantation is 8.9%.
Compared to a group of patients treated by means of
standard chemotherapy and selected according to risk
factors, increased vulnerability to complications was not
associated with the progression of the disease (p=0.024),
including secondary solid tumours, with a similar risk of
acute leukaemia or myelodysplastic syndrome, was de-
monstrated [19]. A characteristic karyotype suggests that
the acute leukaemia one of our patients suffered from
was associated with the therapy which the patient had
undergone. According to one of the reports all the pa-
tients who developed acute leukaemia or myelodyspla-
stic syndrome revealed the presence of cytogenetic ano-
malies already at the time of transplantation. Routine
cytogenetic analysis and disqualification of patients sho-
wing cytogenetic aberrations from transplantation will
prevent the occurrence of similar complications in the
future [20].
The influence of histopathological type of Hodg-
kin’s disease on the effects of transplantation is the obse-
rvation that evoked most doubts. Similar observations
have not been reported by other authors. Particular care
should be taken considering the fact, that we are dealing
with LD type, whose recognition requires increased insi-
ght of the pathomorphologist and the utilisation of mo-
noclonal antibodies [21]. Most of our patients were dia-
gnosed in regional clinics and were not supported by the
analysis of immunophenotypes. For this reason we are
unable to reach final conclusions concerning the influ-
ence of the histological type of Hodgkin’s disease on suc-
cessful transplantation.
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